- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05638295
Testowanie zastosowania AMG 510 (Sotorasib) i Panitumumabu jako ukierunkowanego leczenia nowotworów litych z mutacją KRAS G12C (badanie leczenia ComboMATCH)
Randomizowane badanie fazy II AMG 510 (Sotorasib) z panitumumabem lub bez panitumumabu w zaawansowanych guzach litych: próba leczenia ComboMATCH
This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Panitumumab is in a class of medications called monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. Giving combination panitumumab and sotorasib may kill more tumor cells in patients with advanced solid tumors with KRAS G12C mutation.
Przegląd badań
Status
Szczegółowy opis
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 (sotorasib) alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except colorectal carcinoma [CRC] and non-small cell lung carcinoma [NSCLC]) as measured by progression free survival (Cohort 1).
II. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by response rate (Cohort 2).
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except CRC and NSCLC) as measured by response rate, disease control rate, and overall survival (Cohort 1).
II, To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by disease control rate, progression free survival (PFS), and overall survival (Cohort 2).
III. To further evaluate the safety and tolerability of the combination of AMG 510 (sotorasib) and panitumumab.
IV. To collect tissue and provide it to the ComboMATCH Registration Protocol to assess concordance between the diagnostic tumor mutation profile generated by the Designated Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor-derived deoxyribonucleic acid (DNA) (ctDNA) mutation profile from plasma, as described in ComboMATCH Registration Protocol.
CORRELATIVE EXPLORATORY OBJECTIVES:
I. To investigate the impact of concomitant mutations on the clinical benefit. II. To evaluate if changes in circulating tumor DNA (ctDNA) over time correlate with response to treatment.
III. To evaluate the relative mutant allele fraction of KRAS mutation as a predictor of clinical benefit.
IV. To evaluate if ERK 1/2 and PI3K pathway activation correlate with response and/or resistance.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients who have never received a KRAS G12C inhibitor are randomized to arms A or B.
ARM A: Patients receive sotorasib orally (PO) once daily (QD) on days 1-28 and panitumumab intravenously (IV) on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and computed tomography (CT) or magnetic resonance imaging (MRI) on study.
ARM B: Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
COHORT II: Patients who have received a KRAS G12C inhibitor are assigned to arm C.
ARM C: Patients receive combination therapy as in Arm A.
After completion of study treatment, patients are followed up at 30 days and then every 3-6 months for up to 36 months.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35233
- University of Alabama at Birmingham Cancer Center
-
Mobile, Alabama, Stany Zjednoczone, 36688
- University of South Alabama Mitchell Cancer Institute
-
-
California
-
Los Angeles, California, Stany Zjednoczone, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Stany Zjednoczone, 90025
- The Angeles Clinic and Research Institute - West Los Angeles Office
-
Palo Alto, California, Stany Zjednoczone, 94304
- VA Palo Alto Health Care System
-
-
Florida
-
Aventura, Florida, Stany Zjednoczone, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Stany Zjednoczone, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Coral Springs, Florida, Stany Zjednoczone, 33065
- UM Sylvester Comprehensive Cancer Center at Coral Springs
-
Deerfield Beach, Florida, Stany Zjednoczone, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Hollywood, Florida, Stany Zjednoczone, 33021
- UM Sylvester Comprehensive Cancer Center at Hollywood
-
Jacksonville, Florida, Stany Zjednoczone, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, Stany Zjednoczone, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Stany Zjednoczone, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Stany Zjednoczone, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Stany Zjednoczone, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Stany Zjednoczone, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Stany Zjednoczone, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Stany Zjednoczone, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Stany Zjednoczone, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Stany Zjednoczone, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Stany Zjednoczone, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Stany Zjednoczone, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Stany Zjednoczone, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Stany Zjednoczone, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Barrington, Illinois, Stany Zjednoczone, 60010
- Advocate Good Shepherd Hospital
-
Chicago, Illinois, Stany Zjednoczone, 60612
- University of Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Stany Zjednoczone, 60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake, Illinois, Stany Zjednoczone, 60014
- AMG Crystal Lake - Oncology
-
Danville, Illinois, Stany Zjednoczone, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Stany Zjednoczone, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Stany Zjednoczone, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Downers Grove, Illinois, Stany Zjednoczone, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Stany Zjednoczone, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Stany Zjednoczone, 62401
- Carle Physician Group-Effingham
-
Elgin, Illinois, Stany Zjednoczone, 60123
- Advocate Sherman Hospital
-
Hazel Crest, Illinois, Stany Zjednoczone, 60429
- Advocate South Suburban Hospital
-
Libertyville, Illinois, Stany Zjednoczone, 60048
- Condell Memorial Hospital
-
Libertyville, Illinois, Stany Zjednoczone, 60048
- AMG Libertyville - Oncology
-
Mattoon, Illinois, Stany Zjednoczone, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Stany Zjednoczone, 60153
- Loyola University Medical Center
-
Normal, Illinois, Stany Zjednoczone, 61761
- Carle Cancer Institute Normal
-
Normal, Illinois, Stany Zjednoczone, 61761
- Carle BroMenn Medical Center
-
O'Fallon, Illinois, Stany Zjednoczone, 62269
- Cancer Care Center of O'Fallon
-
Oak Lawn, Illinois, Stany Zjednoczone, 60453-2699
- Advocate Christ Medical Center
-
Oak Lawn, Illinois, Stany Zjednoczone, 60453
- Advocate Outpatient Center - Oak Lawn
-
Palos Heights, Illinois, Stany Zjednoczone, 60463
- Advocate High Tech Medical Park
-
Park Ridge, Illinois, Stany Zjednoczone, 60068
- Advocate Lutheran General Hospital
-
Shiloh, Illinois, Stany Zjednoczone, 62269
- Memorial Hospital East
-
Springfield, Illinois, Stany Zjednoczone, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Stany Zjednoczone, 62702
- Springfield Clinic
-
Springfield, Illinois, Stany Zjednoczone, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Stany Zjednoczone, 61801
- Carle Cancer Center
-
-
Iowa
-
Ankeny, Iowa, Stany Zjednoczone, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Stany Zjednoczone, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Stany Zjednoczone, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Kentucky
-
Lexington, Kentucky, Stany Zjednoczone, 40536
- University of Kentucky/Markey Cancer Center
-
-
Maine
-
Brewer, Maine, Stany Zjednoczone, 04412
- Lafayette Family Cancer Center-EMMC
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Stany Zjednoczone, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, Stany Zjednoczone, 20889-5600
- Walter Reed National Military Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Stany Zjednoczone, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Stany Zjednoczone, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Stany Zjednoczone, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Stany Zjednoczone, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Stany Zjednoczone, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Stany Zjednoczone, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Stany Zjednoczone, 48124
- Corewell Health Dearborn Hospital
-
Farmington Hills, Michigan, Stany Zjednoczone, 48336
- Corewell Health Farmington Hills Hospital
-
Flint, Michigan, Stany Zjednoczone, 48503
- Hurley Medical Center
-
Flint, Michigan, Stany Zjednoczone, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Stany Zjednoczone, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Stany Zjednoczone, 48503
- Cancer Hematology Centers - Flint
-
Lansing, Michigan, Stany Zjednoczone, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Stany Zjednoczone, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Stany Zjednoczone, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Royal Oak, Michigan, Stany Zjednoczone, 48073
- Corewell Health William Beaumont University Hospital
-
Royal Oak, Michigan, Stany Zjednoczone, 48073
- Corewell Health Children's
-
Saginaw, Michigan, Stany Zjednoczone, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Stany Zjednoczone, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Stany Zjednoczone, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, Stany Zjednoczone, 48085
- Corewell Health Beaumont Troy Hospital
-
West Branch, Michigan, Stany Zjednoczone, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Stany Zjednoczone, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Stany Zjednoczone, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Deer River, Minnesota, Stany Zjednoczone, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Stany Zjednoczone, 55805
- Essentia Health Cancer Center
-
Hibbing, Minnesota, Stany Zjednoczone, 55746
- Essentia Health Hibbing Clinic
-
Rochester, Minnesota, Stany Zjednoczone, 55905
- Mayo Clinic in Rochester
-
Sandstone, Minnesota, Stany Zjednoczone, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Stany Zjednoczone, 55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Cape Girardeau, Missouri, Stany Zjednoczone, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Stany Zjednoczone, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Stany Zjednoczone, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Stany Zjednoczone, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Stany Zjednoczone, 63136
- Siteman Cancer Center at Christian Hospital
-
-
Montana
-
Anaconda, Montana, Stany Zjednoczone, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Stany Zjednoczone, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Stany Zjednoczone, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Stany Zjednoczone, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Stany Zjednoczone, 59901
- Logan Health Medical Center
-
Missoula, Montana, Stany Zjednoczone, 59804
- Community Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Stany Zjednoczone, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Stany Zjednoczone, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Jersey
-
New Brunswick, New Jersey, Stany Zjednoczone, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, Stany Zjednoczone, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Buffalo, New York, Stany Zjednoczone, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Stany Zjednoczone, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, Stany Zjednoczone, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
Ohio
-
Columbus, Ohio, Stany Zjednoczone, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Stany Zjednoczone, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Stany Zjednoczone, 43228
- Doctors Hospital
-
Columbus, Ohio, Stany Zjednoczone, 43215
- Grant Medical Center
-
Dayton, Ohio, Stany Zjednoczone, 45415
- Dayton Physician LLC - Englewood
-
Delaware, Ohio, Stany Zjednoczone, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Stany Zjednoczone, 43015
- Grady Memorial Hospital
-
Dublin, Ohio, Stany Zjednoczone, 43016
- Dublin Methodist Hospital
-
Dublin, Ohio, Stany Zjednoczone, 43016
- Columbus Oncology and Hematology Associates
-
Kettering, Ohio, Stany Zjednoczone, 45429
- Kettering Medical Center
-
Mansfield, Ohio, Stany Zjednoczone, 44903
- OhioHealth Mansfield Hospital
-
Marion, Ohio, Stany Zjednoczone, 43302
- OhioHealth Marion General Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Ontario, Oregon, Stany Zjednoczone, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Stany Zjednoczone, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19107
- Thomas Jefferson University Hospital
-
Willow Grove, Pennsylvania, Stany Zjednoczone, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Boiling Springs, South Carolina, Stany Zjednoczone, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, Stany Zjednoczone, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Stany Zjednoczone, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Stany Zjednoczone, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Stany Zjednoczone, 29605
- Prisma Health Cancer Institute - Butternut
-
Greer, South Carolina, Stany Zjednoczone, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Stany Zjednoczone, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Rapid City, South Dakota, Stany Zjednoczone, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Bristol, Tennessee, Stany Zjednoczone, 37620
- Bristol Regional Medical Center
-
Johnson City, Tennessee, Stany Zjednoczone, 37604
- Regional Cancer Center at Johnson City Medical Center
-
Kingsport, Tennessee, Stany Zjednoczone, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Stany Zjednoczone, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Temple, Texas, Stany Zjednoczone, 76508
- Scott and White Memorial Hospital
-
-
Virginia
-
Bristol, Virginia, Stany Zjednoczone, 24201
- Ballad Health Cancer Care - Bristol
-
Charlottesville, Virginia, Stany Zjednoczone, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Stany Zjednoczone, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Stany Zjednoczone, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98122
- Swedish Medical Center-First Hill
-
-
West Virginia
-
Charleston, West Virginia, Stany Zjednoczone, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Appleton, Wisconsin, Stany Zjednoczone, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, Stany Zjednoczone, 54806
- Duluth Clinic Ashland
-
Berlin, Wisconsin, Stany Zjednoczone, 54923
- ThedaCare Cancer Care - Berlin
-
Burlington, Wisconsin, Stany Zjednoczone, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Cudahy, Wisconsin, Stany Zjednoczone, 53110
- Aurora Saint Luke's South Shore
-
Germantown, Wisconsin, Stany Zjednoczone, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Stany Zjednoczone, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Stany Zjednoczone, 54311
- Aurora BayCare Medical Center
-
Janesville, Wisconsin, Stany Zjednoczone, 53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
Kenosha, Wisconsin, Stany Zjednoczone, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Stany Zjednoczone, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Stany Zjednoczone, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Stany Zjednoczone, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marinette, Wisconsin, Stany Zjednoczone, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53233
- Aurora Sinai Medical Center
-
Neenah, Wisconsin, Stany Zjednoczone, 54956
- ThedaCare Regional Medical Center - Neenah
-
New London, Wisconsin, Stany Zjednoczone, 54961
- ThedaCare Cancer Care - New London
-
Oshkosh, Wisconsin, Stany Zjednoczone, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Oshkosh, Wisconsin, Stany Zjednoczone, 54904
- ThedaCare Cancer Care - Oshkosh
-
Racine, Wisconsin, Stany Zjednoczone, 53406
- Aurora Cancer Care-Racine
-
Shawano, Wisconsin, Stany Zjednoczone, 54166
- ThedaCare Cancer Care - Shawano
-
Sheboygan, Wisconsin, Stany Zjednoczone, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Stany Zjednoczone, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Stany Zjednoczone, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waupaca, Wisconsin, Stany Zjednoczone, 54981
- ThedaCare Cancer Care - Waupaca
-
Wauwatosa, Wisconsin, Stany Zjednoczone, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Stany Zjednoczone, 53227
- Aurora West Allis Medical Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-E5 based on the presence of an actionable mutation as defined in EAY191
-
Patient must be enrolled on the ComboMATCH Registration Protocol (EAY191) at the time of registration/randomization to the EAY191-E5 study
-
Patient must be >= 18 years of age
-
Patient must have a KRAS G12C alteration as determined by the ComboMATCH screening assessment
-
Patient must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191-E5)
- NOTE: The current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU) website: www.ctsu.org (final URL pending)
- NOTE: Novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH registration protocol
-
Patient must have cytologically/histologically confirmed advanced/metastatic solid tumor
-
Patient must have progressed on at least one line of standard of care therapy in the advanced/metastatic setting
- NOTE: Patients who have progressed on a prior human epidermal growth factor receptor (EGFR) inhibitor will meet this criterion
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 (or Karnofsky performance status >= 60%)
-
Patient must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) documented by imaging obtained within 28 days prior to registration/randomization
-
Patient must not have any serious active infection within 4 weeks prior to EAY191-E5 registration/randomization (e.g., requiring hospitalization and/or intravenous [IV] antibiotics) or currently receiving oral or IV antibiotics for the treatment of infection. Patients receiving prophylactic antibiotics are eligible
-
Patient must have the ability to retain oral medication and not have any clinically significant gastrointestinal abnormalities that might alter absorption
-
Patient must not have any history of or current evidence of non-infectious interstitial lung disease (ILD)/pneumonitis
-
Patient must not have a history of allergic reactions attributed to either of the study agents or to agents of similar chemical or biologic composition
-
Patient must have completed full treatment cycle 21 days prior to EAY191-E5 registration/randomization if they have received prior chemotherapy, biological cancer therapy, radiation therapy or an investigational agent/device. Patients must have recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from any adverse events due to prior cancer therapy (with the exception of alopecia)
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration/randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for at least 6 months after the last dose of protocol treatment. Patients must not breastfeed while receiving protocol treatment and for one week (7 days) after the last dose of AMG 510 (sotorasib) and 2 months after the last dose of panitumumab
-
Patients must not have neuropathy ≥ grade 2 within 14 days prior to registration/randomization
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Human immunodeficiency virus (HIV)-infected patients no effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac history, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trail, patients should be class 2B or better
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 28 days prior to protocol registration/randomization)
-
Aspartate aminotransferase (AST) (serum (glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase ([SGPT]) < 3 x institutional upper limit of normal (obtained ≤ 28 days prior to protocol registration/randomization)
-
Creatinine =< 1.5 x institutional ULN OR creatinine clearance > 50 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 mg/dL as per Cockcroft-Gault (obtained ≤ 28 days prior to protocol registration/randomization)
-
COHORT I: Patient must not have colorectal cancer or non-small cell lung cancer
-
COHORT I: Patient must not have been previously treated with a KRAS G12C inhibitor
-
COHORT II: Patient must have progressed after treatment at the recommended phase II dose (RP2D) of any KRAS G12C inhibitor
- NOTE: Patients on cohort 1 who experience progression on Regimen 2 (AMG 510 [sotorasib] alone) may be eligible to enroll on cohort 2 and receive combination treatment with panitumumab and AMG 510 (sotorasib). Patients must meet performance status requirements and laboratory values as above and must be begin treatment within 7 days of enrollment. Migration to cohort 2 must take place within 6 months of progression, with no intervening anti-cancer therapy given.
- NOTE: Cohort migration following disease progression is dependent on a slot being available. MATCHBox makes the new treatment assignment following initiation of a step 2 registration for this treatment trial
-
COHORT II: Patient must not have been previously treated with a KRAS G12C inhibitor in combination with an EGFR inhibitor
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Cohort I Arm A (sotorasib, panitumumab)
Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
Inne nazwy:
Undergo collection of blood
Inne nazwy:
Undergo CT scan
Inne nazwy:
Undergo tumor biopsy
Inne nazwy:
Given IV
Inne nazwy:
Given PO
Inne nazwy:
|
|
Aktywny komparator: Cohort I Arm B (sotorasib)
Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
Inne nazwy:
Undergo collection of blood
Inne nazwy:
Undergo CT scan
Inne nazwy:
Undergo tumor biopsy
Inne nazwy:
Given PO
Inne nazwy:
|
|
Eksperymentalny: Cohort II (sotorasib, panitumumab)
Patients receive combination therapy as in Arm A. |
Undergo MRI
Inne nazwy:
Undergo collection of blood
Inne nazwy:
Undergo CT scan
Inne nazwy:
Undergo tumor biopsy
Inne nazwy:
Given IV
Inne nazwy:
Given PO
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Progression-free survival (PFS) (Cohort I)
Ramy czasowe: From registration to documented disease progression or death from any cause, assessed up to 3 years
|
PFS will be compared between the arms using a one-sided log rank test with 10% type I error. Cox's proportional hazards model will be used to estimate the PFS hazard ratio between the treatment arms and a two-sided 80% confidence interval will be reported (to correspond to the one-sided 10% type I error). Confidence intervals on most other quantities will use the two-sided 90% level. |
From registration to documented disease progression or death from any cause, assessed up to 3 years
|
|
Best objective response (Cohort II)
Ramy czasowe: From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
Will be evaluated using the criteria defined by Response Evaluation Criteria in Solid Tumors) version 1.1 for patients with solid tumors. |
From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
|
Overall response rate (ORR) (Cohort II)
Ramy czasowe: From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
The exact 90% confidence interval on the ORR (determined using the method of Atkinson and Brown) will be reported. If the number of analyzable cases is less than 35, a 5% one-sided test will still be used. |
From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall survival (OS) (Cohort I)
Ramy czasowe: Up to 3 years
|
OS distributions by treatment will be estimated and 90% confidence intervals on estimated rates at 6 and 12 months will be reported. The OS hazard ratio will be estimated using Cox proportional hazards model and a 90% confidence interval reported. |
Up to 3 years
|
|
ORR (Cohort I)
Ramy czasowe: Up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
Up to 3 years
|
|
Disease control rates (Cohort I)
Ramy czasowe: From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
|
PFS (Cohort II)
Ramy czasowe: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
|
OS (Cohort II)
Ramy czasowe: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Kristen R Spencer, ECOG-ACRIN Cancer Research Group
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Procesy patologiczne
- Nowotwory
- Procesy Nowotworowe
- Stany patologiczne, oznaki i objawy
- Przerzuty nowotworu
- Aminokwasy, peptydy i białka
- Białka
- Techniki śledcze
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Procedury chirurgiczne, operacyjny
- Techniki cytologiczne
- Cytodiagnoza
- Przeciwciała, monoklonalne, humanizowane
- Przeciwciała, monoklonalne
- Przeciwciała
- Immunoglobuliny
- Immunoproteiny
- Białka krwi
- Globuliny w surowicy
- Globuliny
- Techniki diagnostyczne, chirurgiczne
- Techniki chemii, analityczne
- Analiza widma
- Panitumumab
- Biopsja
- Prowadzenie okazów
- Spektroskopia rezonansu magnetycznego
- sotorasib
Inne numery identyfikacyjne badania
- NCI-2022-09876
- U10CA180820 (Grant/umowa NIH USA)
- NCI-2022-09876 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- EAY191-E5 (Inny identyfikator: CTEP)
- EAY191-E5 (Inny identyfikator: ECOG-ACRIN Cancer Research Group)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .